RMD — ResMed Inc.

ResMed Q2 Fiscal Year 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.42 billion, an 11% increase year-over-year (9% growth in constant currency).
• Gross Margin: 32.3%, up 110 basis points year-over-year and 30 basis points sequentially.
• Operating Profit: Increased by 19%, with operating margin improving to 36.3%.
• Net Income: Increased by 15%, with diluted EPS rising by 16%.
• Cash Flow: $340 million from operations; ended the quarter with $1.4 billion in cash.
• Dividends: Quarterly dividend declared at $0.60 per share; $175 million in share repurchases during the quarter, with plans to exceed $600 million in total for FY 2026.

2. Strategic Updates and Business Highlights

• Product Growth: High single-digit growth in global devices revenue and double-digit growth in masks and accessories.
• Market Expansion: Strong performance in Europe, Asia, and Rest of World with 8% growth in masks and accessories driven by new product launches and strategic initiatives.
• Digital Health Initiatives: Continued focus on enhancing the digital health ecosystem through innovations like AI-enabled therapy settings and new product launches (e.g., F30i Comfort masks).
• Education Initiatives: Significant increase in Continuing Medical Education (CME) programs, with nearly 60,000 completions, indicating a strong push to educate primary care physicians on sleep health.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipated mid-single-digit growth in the residential care software (RCS) business for the next two quarters, with a return to high single-digit growth expected in FY 2027.
• Gross Margin Forecast: Expected to be in the range of 62% to 63% for FY 2026.
• SG&A and R&D: SG&A expenses projected to remain around 19% to 20% of revenue; R&D expenses expected to be 6% to 7% of revenue.

4. Bad News, Challenges, or Points of Concern

• SG&A Growth: SG&A expenses increased by 15%, outpacing revenue growth, raising concerns about cost management.
• Competitive Landscape: Potential re-entry of Philips into the U.S. market remains a concern, although ResMed is confident in its product offerings and market position.
• Regulatory Environment: Ongoing monitoring of global trade and regulatory changes, particularly related to tariffs and competitive bidding programs.

5. Notable Q&A Insights

• GLP-1 Impact: The introduction of GLP-1 medications is positively influencing patient engagement and adherence to CPAP therapy, with a noted 10%-11% higher start rate for patients on these medications.
• Patient Funnel: ResMed is seeing increased motivation among patients entering the healthcare system, attributed to both GLP-1 medications and increased awareness from big tech.
• Market Dynamics: The company is focused on leveraging its digital health capabilities and partnerships to enhance patient pathways and improve adherence rates.
• Future Growth: ResMed aims to maintain or exceed high single-digit growth in masks and accessories, despite market challenges.

Overall, ResMed reported strong financial performance in Q2 FY 2026, driven by product innovation, strategic market initiatives, and a robust digital health ecosystem, while also navigating challenges related to competitive pressures and cost management.